Nov 8/26- Added more information on LADA treatment. Note that treatment on LADA is not on the exam (LADA itself may not show up on the exam) as it is outside of the guidelines and is a area of active research. I do have two patients with LADA (who also see an endocrinologist) so LADA will likely show up in your clinical practice eventually. With better testing I do expect you to encounter more and more LADA patients in real life, though it will be rare. Treatment should be done in consultation with a endocrinologist. I’m putting the info at the bottom of the Chapter 12 2025 Update/Chapter 34/new Chapter 41- Glycemic Management Across the Lifespan for People With Type 1 Diabetes study guide.
Nov 5/26- Added a GLP-1 equivalency chart for daily, oral, and weekly GLP-1 analogs to the 2024 chapter 13- Pharmacological Management of Type 2 Diabetes User Guide
Nov 2/26- Added information on Nonarteritic anterior ischemic optic neuropathy (NAION, which in severe cases can cause vision loss) which can be a side effect information of GLP-1 analogs to chapter 30- retinopathy study guide. Several patients have been asking me about NAION as they are on Ozempic and concerned about their vision.
Oct 30/26- Added additional Maturity-Onset Diabetes of the Young (MODY) information and risk calculator to chapter 3 study guide
Reload document 
Open in new tab